Supporting Information

Maruyama et al. 10.1073/pnas.1010559107



Fig. 51. Overall view of experimental outline, sense and antisense tag count distributions, and identity and function of 252 AS genes common among normal CD24.P samples. (*A*) Flow chart of SAGE-Seq experiment and data analysis. (*B*) Total counts of sense and antisense tags in each library. IDC, invasive ductal carcinoma; N, nulliparous; P, parous. CD24, CD44, EPCR, and SSEA4 indicate the cell surface markers used for the isolation of the epithelial cells (details presented in Table S1). (C) Box plots depicting sense and antisense tag counts per gene in each sample. The box indicates the 25th and 75th percentiles; the white bar indicates the median; the whiskers extend to the most extreme data point, which is no more than 1.5 times the interquartile range from the box; and outliers are plotted as small dots. (*D*) Number of S and SAS genes in each sample. (*E*) Box plots depicting sense and antisense tag counts be z5th and 75th percentiles; the white bar indicates the median; the whiskers extend to the most extreme data point, which is no more than 1.5 times the interquartile range from the box; and percentage of antisense in each sample. In box plots, the box indicates the 25th and 75th percentiles; the white bar indicates are plotted as small dots. (*F*) Functional annotation of common AS genes in CD24.P samples based on (GO) terms, including biological processes and cellular localization.



Fig. 52. Characterization of AS genes. (*A*) Venn diagrams depicting the number of overlapping AS genes among CD44⁺ cell samples. (*B*) Scatterplot depicting percentage of antisense tags per gene relative to total tag counts in 323 AS genes common among CD44P cells in normal (blue) and cancer (red) samples. Orange lines mark the 80% and 20% values, which were used as criteria for gene classification into AS, S, and SAS groups. A list of these genes is presented in Dataset 52. (C) Hierarchical cluster analysis of all samples based on 323 AS genes common among CD44P cells. The color scale indicates percentage of antisense tag counts in each gene. (*D*) Box plots depicting sense and antisense tag counts derived from 323 AS genes in each sample. The box indicates the 25th and 75th percentiles; the white bar indicates median; the whiskers extend to the most extreme data point, which is no more than 1.5 times the interquartile range from the box; and outliers are plotted as small dots. (*E*) Venn diagram shows the number of union of AS genes in all normal samples (blue) and cancer (*Right*) samples. (*G*) GO term enrichment analysis of 1,975 normal-specific AS genes. The bar graph represents the $-\log_{10} P$ value for the enrichment of the indicated GO term. The top 10 GO terms are shown in the graph. (*H*) Overall correlation between antisense and sense tag counts in all samples. A heat map of S and AS gene expression profiles for all the samples is shown. The \log_2 ratio is applied to the normalized count of all expression profiles before calculation of the cross-correlation. Red indicates higher correlation, and antisense normal, and antisense cancer (*Lower Left* to *Upper Right*).



Fig. S3. Validation of AS genes using various approaches. (A) Representative example of tag distributions in selected genes based on ASSAGE. ASSAGE tag density from two cancer samples (T1 and T2) and one normal sample (N1) are plotted along with gene structures. Green and red mark tags derived from plus and minus strands, respectively. Gene structure and gene names are depicted under the graph; the box represents an exon; and the line represents an intron. Red and blue colors of the gene names indicate that the gene is a plus- and minus-strand gene, respectively. ASSAGE tag counts are normalized to 5 million per sample, and tag density in 10-bp windows is calculated assuming that each fragment size is 300 bp. The scale of the y axis is fixed, whereas the scale of the x axis is variable and correlates with the size of the genes. In the first example, APOL1 is a plus-strand gene, and only sense tags (plus-strand tags in this case) are

observed in two cancer samples, whereas in the normal sample, high levels of antisense tags (minus-strand tags) are also observed. (*B*) Validation of antisense transcripts using custom oligonucleotide arrays. Processed signals for each probe were obtained from Agilent Technologies Feature Extraction software and converted to a \log_2 scale. One probe showing the highest average signal was selected from five probes for each sense and antisense transcript. In the heat map, each row corresponds to each gene, which has both sense and antisense transcripts. Signals for antisense transcripts were observed together with signals for sense in four cancer samples. The blue color indicates the intensity in the \log_2 scale. (C) Sense and antisense tag distribution patterns in RICTOR. Sense (green) and antisense (red) tag positions are shown across the gene structure. The left-to-right direction of the x axis corresponds to the 5'- to 3'-end of the indicated gene. The height of the bar represents normalized tag counts for each tag. (*D*) Sense and antisense tag distribution patterns in NLRC3. Sense (green) and antisense (red) tag positions are shown across the gene structure. The left-to-right direction of the x axis corresponds to the 5'- to 3'-end of the indicated gene. The height of the bar represents normalized tag counts for each tag. (*E*) Effect of antisense lncRNA on Rictor protein levels. (*Upper*) Immunoblot analysis of each tag. (*E*) Effect of antisense lncRNA on Rictor protein levels. (*Upper*) and Rictor sense (S1 and AS2) targeting siRNAs. (*Lower*) Immunoblot analysis of Rictor protein and phospho-Ser 473 Akt levels in human mamary epithelial cells cultured at 20% O₂ or 1% O₂ transfected with control (C) and Rictor sense (S1 and AS2) targeting siRNAs.

Table S1. Summary of tissue samples used for the indicated experiments

| SAGE-Seq | ASSAGE | Array | Tissue | Cell type | Differentiation status | Histology | Grade | ER | PR | HER2 |
|-------------|--------|-------|--------|-----------|---------------------------|---------------------------------|-------|-----|-----|------|
| EPCR.IDC27 | | | IDC27 | EPCR | Progenitor-like | Invasive ductal carcinoma, male | | Pos | Pos | Neg |
| EPCR.IDC31 | | | IDC31 | EPCR | Progenitor-like | Inflammatory cancer | Н | Neg | Neg | Pos |
| CD24.IDC31 | | | | CD24 | Luminal epithelial | | | | | |
| CD24.IDC34 | | | IDC34 | CD24 | Luminal epithelial | Invasive lobular carcinoma | IM | Pos | Neg | Neg |
| CD24.IDC36 | | | IDC36 | CD24 | Luminal epithelial | Invasive ductal carcinoma | IM/H | Pos | Pos | Pos |
| CD24.IDC38 | | | IDC38 | CD24 | Luminal epithelial | Invasive ductal carcinoma | IM | Pos | Pos | Neg |
| SSEA4.IDC38 | | | | SSEA4 | Progenitor-like | | | | | |
| CD24.IDC40 | T1 | | IDC40 | CD24 | Luminal epithelial | Invasive ductal carcinoma | Н | Neg | Neg | Pos |
| SSEA4.IDC40 | | | | SSEA4 | Progenitor-like | | | | | |
| | T2 | T2 | PE18 | CD24 | Luminal epithelial | Pleural effusion | | Neg | Neg | Pos |
| CD24.N1 | | | N33 | CD24 | Luminal epithelial | Normal, nulliparous | NA | NA | NA | NA |
| CD24.N3 | | | N35 | CD24 | Luminal epithelial | Normal, nulliparous | NA | NA | NA | NA |
| CD24.N4 | | | N47 | CD24 | Luminal epithelial | Normal, nulliparous | NA | NA | NA | NA |
| CD44.N4 | | | | CD44 | Progenitor-like | Normal, nulliparous | | | | |
| CD24.N5 | | | N48 | CD24 | Luminal epithelial | Normal, nulliparous | NA | NA | NA | NA |
| CD44.N5 | | | | CD44 | Progenitor-like | Normal, nulliparous | | | | |
| CD24.P1 | | | N37 | CD24 | Luminal epithelial | Normal, parous | NA | NA | NA | NA |
| CD44.P1 | | | | CD44 | Progenitor-like | | | | | |
| CD24.P2 | | | N39 | CD24 | Luminal epithelial | Normal, parous | NA | NA | NA | NA |
| CD44.P2 | | | | CD44 | Progenitor-like | | | | | |
| CD24.P3 | | | N40 | CD24 | Luminal epithelial | Normal, parous | NA | NA | NA | NA |
| CD44.P3 | | | | CD44 | Progenitor-like | | | | | |
| | N1 | | N58 | CD24 | Luminal epithelial | Normal, nulliparous | NA | NA | NA | NA |
| | | Т3 | IDC42 | Bulk | NA | Invasive ductal carcinoma | Н | Pos | Pos | Pos |
| | | T4 | IDC50 | ESA | Luminal epithelial | Invasive ductal carcinoma | н | Neg | Neg | Neg |
| | | T5 | PE2 | Bulk | NA | Pleural effusion | NA | NA | NA | NA |

Name of the SAGE-Seq and ASSAGE libraries, tissue code, cell surface marker used for isolation, differentiation status of the cells, histology, tumor grade (H, high; IM, intermediate; L, low), estrogen receptor (ER) and progesterone receptor (PR), and HER2 status (Pos, positive; Neg, negative) are listed. ESA, epithelial surface antigen; IDC, invasive ductal carcinoma; NA, nonapplicable.

| Table S2. | Summary of differential | y expressed genes | |
|------------|-------------------------|--------------------|-----------|
| Transcript | Di | fferential pattern | No. genes |
| Sense | Ν | lormal < Cancer | 5,017 |
| | Ν | lormal > Cancer | 2,291 |
| Antisense | М | lormal < Cancer | 1,322 |
| | Ν | lormal > Cancer | 2,044 |
| | Differe | ential pattern | |
| | Sense | Antisense | No. genes |
| 1 | N < C | N < C | 810 |
| 2 | N < C | N > C | 404 |
| 3 | N < C | N = C | 3,803 |
| 4 | N > C | N > C | 688 |
| 5 | N > C | N < C | 74 |
| 6 | N > C | N = C | 1,529 |
| 7 | N = C | N < C | 438 |
| 8 | N = C | N > C | 952 |

Differentially expressed genes were identified based on the log_2 ratio of normalized gene tag counts applying the significance analysis of microarray algorithm. Genes with differential sense or antisense counts between normal and cancer samples were identified using a 1% FDR as the cutoff for significance.

Table S3. Comparison of ASSAGE and SAGE-Seq data: Summary of ASSAGE read counts

| Library name | Raw reads | Aligned reads | % Aligned | + Strand | Strand |
|--------------|------------|---------------|-----------|-----------|----------------------------|
| T1 | 10,711,873 | 6,130,300.00 | 57.2 | 3,145,196 | 2,985,104 |
| T2 | 13,047,359 | 8,799,516.00 | 67.4 | 4,370,183 | 4,429,333 |
| N1 | 12,752,300 | 1,832,358.00 | 14.4 | 915,515 | 916,843 |

T1 and T2 are CD24⁺ cells purified from two different breast carcinomas, and N1 is normal CD24⁺ cells.

PNAS PNAS

| Ensemble ID | Symbol | PBMC | HCT116 | Jurkat | Jurkat2 | Miapaca2 | MRC5 | MRC5 2 | 11 | -2 N1 | Gene class in Normal | Gene class in Cancer | % Normal | % Cancer | Sense Normal | Sense Cancer | Antisense Normal | Antisense Cancer |
|-------------------|----------------|----------|------------|-----------|-----------|----------------|-----------|--------------|-----------|-----------|-------------------------|-------------------------|-------------|-------------|-----------------|-----------------|---------------------|---------------------|
| ENSG00000184788 | SATL1 | NA | 100.0 | ٨A | 91.7 | 100.0 | AN | 1 1 | 00.00 | -7 NA | AS | AS | 97.8 | 94.2 | 0 | ٦ | 9 | 10 |
| ENSG00000196407 | THEM5 | 100.0 | NA | ΝA | AN | NA | AN | NA 1 | 00.00 N/ | A 100 | 0 AS | AS | 93.4 | 91.5 | - | - | 6 | 8 |
| ENSG00000145721 | LIX1 | 100.0 | AA | ΝA | AN | NA | AN | A A V | IA N | A 100 | 0 AS | AS | 100.0 | 100.0 | 0 | 0 | 13 | 7 |
| ENSG00000128617 | OPN1SW | NA | 100.0 | ٨A | AN | 100.0 | 100.0 | 100.0 1 | 00.0 10 | 0.0 100 | 0 AS | SAS | 99.9 | 70.8 | 0 | 36 | 161 | 87 |
| ENSG00000080644 | CHRNA3 | NA | ΝA | 0.0 | 5.4 | NA | AN | AA AV | IA 77 | .8 100 | 0 AS | AS | 96.9 | 98.9 | - | - | 16 | 71 |
| ENSG00000205923 | CEMP1 | 95.8 | 91.7 | 100.0 | 96.6 | 100.0 | 100.0 | 92.9 1 | 00.0 10 | 0.0 100. | 0 AS | SAS | 99.9 | 78.9 | 0 | 2 | 104 | 8 |
| ENSG00000204352 | C9orf129 | ΝA | ΝA | ΝA | ٩N | NA | AN | NA 6 | 3.3 N/ | A 100 | 0 AS | AS | 96.2 | 83.6 | 4 | 2 | 91 | 6 |
| ENSG00000183260 | C20orf135 | 100.0 | NA | 100.0 | 100.0 | 100.0 | NA | 100.0 | 00.0 10 | 0.0 100. | 0 SAS | AS | 79.9 | 93.2 | 9 | 2 | 23 | 26 |
| ENSG00000128346 | C22orf23 | ΝA | ΝA | ΝA | 100.0 | NA | ΝA | 100.0 9 | 8.6 98 | .8 97.2 | AS | AS | 94.8 | 85.7 | 12 | 5 | 213 | 33 |
| ENSG00000137674 | MMP20 | ΝA | ΝA | ٨A | AN | NA | AN | AA A | IA N | A 93.2 | AS | AS | 98.1 | 84.7 | - | ٦ | 34 | Ŋ |
| ENSG00000188493 | C19orf54 | 6.7 | 8.3 | 0.0 | 3.6 | 0.0 | 0.0 | 11.8 2 | 2.7 17 | .1 81.6 | AS | SAS | 88.8 | 77.3 | 9 | 5 | 44 | 18 |
| ENSG00000168280 | KIF5C | 0.0 | 0.0 | ٨A | ΝA | NA | AN | VA 2 | 5.0 12 | .1 77.4 | AS | AS | 100.0 | 97.8 | ß | 20 | 11223 | 906 |
| ENSG00000196860 | TOMM20L | ΝA | ΝA | ٨A | AN | NA | AN | NA 3 | 1.3 73 | .3 33.3 | AS | AS | 95.0 | 89.7 | 0 | ٦ | 6 | 11 |
| ENSG00000166035 | LIPC | 36.4 | 80.0 | ٨A | 41.7 | 51.9 | AN | 33.3 5 | 4.5 72 | .0 NA | AS | AS | 88.6 | 92.7 | - | - | 7 | 7 |
| ENSG00000165521 | EML5 | 28.6 | 20.0 | 3.7 | 1.4 | NA | AN | LA 1 | 2.1 64 | .0 6.8 | SAS | AS | 83.1 | 91.1 | ъ | m | 23 | 30 |
| ENSG00000100095 | SEZ6L | 9.4 | ΝA | ٨A | 66.7 | NA | AN | NA 5 | 8.8 54 | .5 NA | AS | AS | 97.7 | 93.3 | - | 1 | 26 | 7 |
| ENSG00000135144 | DTX1 | 22.2 | NA | 3.2 | 5.3 | NA | AN | NA 5 | 7.1 5. | 4 33.3 | AS | SAS | 93.0 | 75.1 | ъ | m | 71 | 6 |
| ENSG00000165490 | C11orf82 | ΝA | 0.0 | 0.0 | 0.0 | 0.0 | AN | NA C | 0. N | A 50.0 | AS | AS | 99.9 | 89.4 | 0 | 10 | 91 | 83 |
| ENSG00000213311 | C11orf82 | ΝA | AA | ٨A | AN | NA | AN | NA C | .0 N | A 50.0 | AS | AS | 99.9 | 89.4 | 0 | 10 | 91 | 83 |
| ENSG00000160050 | CCDC28B | 32.0 | 37.5 | 8.0 | 11.8 | 5.9 | 52.9 | 38.5 4 | 6.7 4. | 3 20.0 | AS | SAS | 88.3 | 79.7 | - | ٦ | 11 | Ŋ |
| ENSG00000101695 | RNF125 | 0.9 | 0.0 | 8.3 | 0.0 | 0.0 | NA | NA 4 | 2.9 14 | .9 10.0 | SAS | SAS | 70.5 | 71.6 | 74 | 24 | 177 | 61 |
| ENSG00000196787 | HIST1H2AG | 0.0 | 1.0 | 0.0 | 1.9 | 0.0 | 0.0 | 0.0 | .0 29 | .4 0.0 | AS | SAS | 83.3 | 70.5 | - | 9 | 7 | 14 |
| ENSG00000136531 | SCN2A | 0.0 | AN | ٨A | ΝA | NA | 0.0 | 25.0 N | IA 21 | .4 NA | AS | AS | 98.6 | 84.8 | 0 | 11 | ø | 59 |
| ENSG00000147003 | TMEM27 | ٨A | AN | ٨A | ΝA | NA | AN | NA 1 | 3.3 11 | .1 0.0 | AS | AS | 93.6 | 96.9 | S | - | 68 | 26 |
| ENSG00000105926 | MPP6 | 3.4 | 1.6 | 5.3 | 0.0 | 0.0 | 0.0 | 1.5 4 | .7 13 | .2 1.7 | SAS | AS | 83.3 | 86.1 | 22 | 12 | 110 | 76 |
| ENSG00000173457 | PPP1R14B | NA | 25.0 | ٨A | 3.7 | 20.0 | 16.7 | 33.3 0 | .0 10 | .0 2.5 | SAS | AS | 73.3 | 83.9 | 18 | m | 48 | 18 |
| ENSG00000116133 | DHCR24 | 26.3 | 0.3 | 0.4 | 0.0 | 0.4 | 0.0 | 1.1 0 | 8 | 2 0.0 | SAS | SAS | 77.1 | 81.8 | 10 | 17 | 33 | 74 |
| ENSG00000170088 | TMEM192 | 0.0 | 9.1 | ٨A | 11.1 | NA | ΔN | NA 3 | .9 .4 | 5 0.0 | SAS | SAS | 76.2 | 72.6 | 10 | 23 | 32 | 60 |
| ENSG00000048471 | SNX29 | 0.9 | 12.5 | 3.6 | 2.7 | 26.7 | 3.1 | 2.3 | .0 | 4 2.1 | AS | SAS | 94.8 | 71.7 | 41 | 39 | 753 | 66 |
| ENSG0000006075 | CCL3 | ٨A | NA | ٨A | ΝA | NA | AN | A A | IA 2. | NA I | AS | AS | 99.9 | 99.9 | 0 | - | 79 | 607 |
| ENSG00000206262 | C3orf72 | ٨A | NA | NA | ΝA | NA | ΝA | AA AV | IA N | A NA | AS | AS | 100.0 | 100.0 | 0 | 0 | 20 | 9 |
| ENSG00000106436 | MYLC2PL | NA | AN | ٨A | ΝA | NA | AN | AA A | IA N | AN A | AS | AS | 100.0 | 100.0 | 0 | 0 | 145 | 16 |
| ENSG00000185960 | SHOX | NA | ΝA | ٨A | ΝA | NA | NA | AA AV | IA N | A NA | AS | AS | 100.0 | 100.0 | 0 | 0 | 10 | 6 |
| ENSG0000185823 | C15orf2 | ٨A | ΝA | ٨A | ΝA | NA | AN | A A | IA N | A NA | AS | AS | 89.1 | 94.5 | - | 0 | 12 | 5 |
| ENSG00000188000 | OR7D2 | NA | ΝA | ٨A | ΝA | NA | NA | AA AV | IA N | A NA | AS | SAS | 0.66 | 71.7 | 0 | 2 | 13 | 12 |
| ENSG0000161905 | ALOX15 | ٨A | NA | NA | ΝA | NA | ΝA | AA AV | IA N | A NA | AS | AS | 100.0 | 96.2 | 0 | - | 27 | 16 |
| ENSG00000105996 | HOXA2 | NA | AN | ΝA | ΝA | NA | 40.0 | 46.2 N | IA N | 0.0 ۲ | AS | SAS | 97.2 | 70.8 | 0 | 2 | 8 | 4 |
| Comparison of our | ASSAGE (red | 1. tumor | : blue, nc | ormal) ar | S-39AGE-S | seg (black) di | ata as we | II as previo | uslv repo | irted ASS | AGE (green) da | ita (1). A total | of 9,550 c | ienes com | mon betv | veen the | two datasets | (our data |

and the Johns Hopkins University data) were used for the comparison. The percentage of antisense for active percentage of antisense for each gene was calculated the same way in ASAGE data. NA, total (sense + antisense) tag count is <5. Gene class, percentage of antisense, and sense and antisense tag count is <5. Gene class, percentage of antisense, and sense and antisense tag count is <5. Gene class, percentage of antisense, and sense and antisense tag counts for each gene in averaged normal and cancer data are shown. About 30% of common AS genes in SAGE-Seq also showed a high percentage of AS genes in ASSAGE data, but about 50% of them were not detected by ASSAGE, likely attributable to lower sequencing depths.

1. Saha S, et al. (2002) Using the transcriptome to annotate the genome. Nat Biotechnol 20:508-512.

PNAS PNAS

Table 54. Comparison of ASSAGE and SAGE-Seq data: Common AS genes detected in both normal and cancer samples by SAGE-Seq

Dataset S1. Summary of SAGE-Seq tag counts in each sample and number of genes classified as S (sense predominant), AS (antisense predominant), and SAS (both sense and antisense) in each sample

Dataset S1

Dataset S2. Identity of 252 AS genes common among three CD24.P (blue) samples and 323 AS genes common among three CD44.P (red) samples

Dataset S2

PNAS PNAS

A list of genes with the gene symbol, the GenBank accession number, and a description is provided.

Dataset S3. Function of 252 AS genes common among three CD24.P (blue) samples, 323 AS genes common among three CD44.P (red) samples, and a union of all AS genes (1,975 genes in total) detected only in normal samples (black)

Dataset S3

Functional categories of genes are based on GO term analysis. GO term category, term, number (count), and percentage (%) of genes in category as well as P values are listed. Only GO terms with P < 0.05 are shown.

Dataset S4. Dataset S4.List of differentially expressed genes between normal and cancer samples

Dataset S4

(A) List of genes that show higher sense tag counts in cancer compared with normal and higher antisense tag counts in normal compared with cancer samples. (B) List of genes that show higher sense tag counts in cancer compared with normal and higher antisense tag counts in cancer compared with normal and cancer samples, respectively.